Zobrazeno 1 - 10
of 13
pro vyhledávání: '"11"'
Autor:
S. Naik, S. Kuckreja, A. Sethuraman, A. D’Souza, S. Kumar, S. Jiwani, O. Taylor, G. Gamtiksulashvili, U. Ekeowa, K. Patrick, S. Waring, Peter Russell, Y. Narayan, Muhammad Anwar, G. Collins, R. Ragatha
Publikováno v:
The wider impact of the pandemic.
P104 Table 1Mortality rate after presentation of COVID-19 by: tumour type, time from cancer diagnosis, cancer stage, progression of disease, and systemic anti-cancer treatment (SACT). Number mortality number mortality% odds ratio Cancer type Solid or
Autor:
P Tongue, E Castells, G Elliot, Peter Bradding, S Mason, Katy M. Roach, H Marshall, Latifa Chachi, Matthew Richardson
Publikováno v:
Modelling lung disease in vitro/vivo.
Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive and invariably lethal interstitial lung disease. Animal models help with understanding disease mechanisms, but to-date, the bleomycin mouse model of lung fibrosis has failed to predict
Autor:
Anna Moore, L Estrada, Manuel Lozano-Garcia, GF Rafferty, Caroline J. Jolley, Psp Cho, S Maxwell, Hannah Fletcher, Abel Torres, John Moxham, Raimon Jane, M Crossley
Publikováno v:
An update in lung physiology.
Introduction and objectives Heart failure is a common comorbidity of COPD and contributes to increased breathlessness and adverse clinical outcomes. Neural respiratory drive (NRD) is closely related to breathlessness intensity in COPD. This study aim
Autor:
Alan S. Brody, Gautham Marigowda, Jonathan G. Goldin, Felix Ratjen, Linda T Wang, David Waltz, C Hug, Scott K. Nagle
Publikováno v:
Cystic fibrosis: disease trajectory and evolving therapies.
Objective To evaluate the effects of lumacaftor/ivacaftor (LUM/IVA) combination therapy on lung morphology and physiology with computed tomography (CT) scanning in patients aged 6 to 11 years with cystic fibrosis (CF) homozygous for the F508del-CFTR
Publikováno v:
An update in screening for lung cancer.
Liverpool has high levels of deprivation and one of the highest rates of respiratory morbidity in England with double the incidence of lung cancer, most prevalent in the lower socioeconomic groups. To tackle this health inequality, in February 2016 i
Publikováno v:
Modelling lung disease in vitro/vivo.
Rationale We recently identified a polymorphism associated with the AKAP13 gene resulted in higher levels of AKAP13 gene expression and Idiopathic pulmonary fibrosis (IPF) susceptibility. Furthermore, higher expression of AKAP13 were associated with
Publikováno v:
It’s all about your image: new approaches to thoracic imaging.
Introduction Total Lung capacity (TLC) is often measured in patients with advanced lung disease to help inform diagnosis, severity and management. However, some may not manage or tolerate the technical aspects of the gold standard test: whole body pl
Publikováno v:
Developing pleural and interventional services.
Introduction Indwelling pleural catheters (IPC) have increasingly been used as a therapeutic option to manage recurrent pleural effusions. IPCs are the preferred method of management for symptomatic effusion with non-expandable lung (NEL). Aims and o
Publikováno v:
Cancer screening and follow up.
Introduction The optimum follow-up of patients who have undergone surgical resection of lung cancer is yet to be agreed. Within the local NHS trust, the standard post-operative follow-up in the first two years changed from chest radiographs (CXR) to
Autor:
Robert J. Hallifax, Najib M. Rahman, John P. Corcoran, Maged Hassan, Ioannis Psallidas, Rachelle Asciak, Rachel M. Mercer, A Yousuf
Publikováno v:
Closing the flood gates of the pleura.
Background Over 50 000 patients with malignant pleural effusion (MPE) are seen annually in the UK. The majority develop recurrent symptomatic disease requiring definitive treatment. MPE is most frequently managed with talc slurry pleurodesis via inte